Program
GIPR Agonist LY3537021
In Eli Lilly’s pipeline, GIPR agonist
. Its studies are mostly in Nausea · Diabetes Mellitus, Type 2, led by Eli Lilly.
Furthest: phase 2, since Sep 5, 20253 company-led studies, 1 open or runningNext primary completion: Dec 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 31 open or running | phase 2since Sep 5, 2025 | Oct 12, 2020 | Dec 2026phase 2 · NCT07169851 |
- Named in Eli Lilly’s own pipeline as
GIPR Agonist Long Acting
, phase 2, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 12, 2020First study: phase 1 study in Diabetes Mellitus, Type 2First studyNCT04586907 · 85 enrolled · Singapore
- Jun 30, 2022Phase 1 study in HealthyNCT05444569 · 47 enrolled · Singapore
- Sep 5, 2025Phase 2 study in NauseaNCT07169851 · 204 planned · United States, Australia, China and more
Ahead
- Dec 2026Primary completion: phase 2 study in NauseaNCT07169851
TargetBeta
“GIPR agonist”the company's pipeline, read by Claude · source
“A long-acting glucose-dependent insulinotropic polypeptide receptor (GIPR) agonist, with potential weight-reducing, anti-diabetic, anti-nauseant and anti-emetic activities. Upon subcutaneous administration, GIPR agonist LY3537021 targets, binds to and activates GIPR. This may moderate nausea and …”NCIt, read by Claude
“A long-acting glucose-dependent insulinotropic polypeptide receptor (GIPR) agonist, ”NCIt, by rule
Other programs on GIPR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Tirzepatiderule | Eli Lilly | phase 4 | 72 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| brenipatide | Eli Lilly | phase 3 | 19 |
| olatorepatide | Hansoh Pharmaceutical Group | phase 3 | 12 |
| UBT251 | The United Laboratories International | phase 3 | 12 |
| enicepatide | Hoffmann-La Roche | phase 3 | 10 |
| VK2735rule | Viking Therapeutics | phase 3 | 8 |
| NNC0519-0130 | Novo Nordisk | phase 2 | 11 |
| macupatide | Eli Lilly | phase 2 | 8 |
| BI 3034701 | Boehringer Ingelheim | phase 2 | 6 |
| HRS-4729 | Jiangsu HengRui Medicine | phase 2 | 5 |
| NA-931rule | biomed-industries-inc | phase 2 | 3 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07169851Nausea · United States, Australia, China and more | 2 | Recruiting | Dec 2026 | 204 |
| NCT05444569Healthy · Singapore | 1 | Completed | Feb 24, 2023 | 47 |
| NCT04586907Diabetes Mellitus, Type 2 · Singapore | 1 | Completed | Nov 30, 2021 | 85 |
How it is read
Names in the registry
- “LY3537021”, 3 entries
Conditions, from the studies’ own filings
- Nausea, 1 study
- Diabetes Mellitus, Type 2, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.